Standardized Treatment Eliminates Outcome Disparities in Non-Metastatic Osteosarcoma
Survival outcomes for patients on the EURAMOS-1 trial were not affected by race/ethnicity or poverty exposure.
Sarcoma
High-Dose Ifosfamide Bests Topotecan-Cyclophosphamide in Relapsed/Refractory Ewing Sarcoma
Ifosfamide improved event-free and overall survival.
Persistent Opioid Use After Sarcoma Treatment Explored Among Youth
Twenty-three percent of adolescents and young adults with sarcoma who used opioids during treatment had new persistent opioid use after treatment.
Nivolumab-Ipilimumab Plus Cryoablation in Pediatric, Young Adult Patients With Relapsed/Refractory Solid Tumors
In a phase 2 study, researchers are investigating the combination of cryoablation and dual checkpoint inhibition.
Lurbinectedin Deemed “Valuable” Treatment Option for Relapsed Ewing Sarcoma
Lurbinectedin produced an overall response rate of 14.3% and a disease control rate of 57.1%.
Intensification Does Not Improve Survival in Metastatic Ewing Sarcoma
High-dose treosulfan plus melphalan followed by autologous stem cell reinfusion did not improve event-free or overall survival.
Molecular Profiling Can Guide Treatment After Recurrence in Young Cancer Patients
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
Eponyms in Oncology: Li-Fraumeni Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Li-Fraumeni syndrome.
No PFS Benefit With Carotuximab in Advanced Angiosarcoma
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Irinotecan-Temozolomide “Effective and Safe” for Relapsed Ewing Sarcoma
In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.
- Loading...
Loading...
Next post in Bone Cancer
Loading... 
Loading...